Search
Lanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedLanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. … It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects.
Vinblastine
go.drugbank.com/drugs/DB00570ApprovedInvestigationalAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexMaduramicin
go.drugbank.com/drugs/DB11525ExperimentalVet approvedMaduramicin is an antiprotozoal agent used in veterinary medicine as prophylaxis against coccidiosis. … It is a naturally occurring compound which was first isolated from the actinomycete, Actinomadura rubra.
AS-8112
go.drugbank.com/drugs/DB09207ExperimentalAS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant
Human Interleukin 8
go.drugbank.com/drugs/DB16456InvestigationalInterleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).
Cetrorelix
go.drugbank.com/drugs/DB00050ApprovedInvestigationalCetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH).
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine is the dextrorotatory enantiomer of amphetamine . Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.
Mixtures: Mixed Salts of a Single-Entity Amphetamine Product, Mixed Salts of a Single-Entity Amphetamine ProductADL 10-0101
go.drugbank.com/drugs/DB05443ExperimentalADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. … Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects.